Michael A. Metzger is the CEO of Syndax Pharmaceuticals, a biotech company focused on innovative cancer therapies. He took on the role in February 2022 after serving as the company's President and Chief Operating Officer. With a background in economics...

Michael A. Metzger is the CEO of Syndax Pharmaceuticals, a biotech company focused on innovative cancer therapies. He took on the role in February 2022 after serving as the company's President and Chief Operating Officer. With a background in economics from the University of Pennsylvania, Michael has a solid foundation for business management. His compensation reflects his leadership impact; in 2023, he earned a total of $900,000, which includes a hefty performance-based bonus. Interestingly, he has been actively involved in shaping corporate goals and objectives through the Compensation Committee. Michael has a track record of significant stock awards, with 20,000 shares vesting in 2023, highlighting his alignment with company success. His strategic vision at Syndax has been recognized, especially as the company navigates the ever-changing pharmaceutical landscape, focusing on revenue growth and operational milestones. His journey mirrors a fascinating blend of business acumen and industry knowledge, driving innovation at Syndax.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Syndax Pharmaceuticals CEOs

S

Michael A. Metzger

CEO of Syndax Pharmaceuticals

Education

B.A. in Economics from University of Pennsylvania

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

May 15, 1973 - 52 years ago

CEO of Syndax Pharmaceuticals for

3 years 5 months (Feb 2022 - Present)

Previous Experience

President and Chief Operating Officer at Syndax Pharmaceuticals, Inc.

Rivals

Competitors/colleagues of Michael A. Metzger

Holdings

See how much did Michael A. Metzger make over time.

Michael A. Metzger holds a significant stake in Syndax Pharmaceuticals. In 2023, he had 20,000 shares vest from a long-term incentive plan, translating to a vested stock value of $300,000. His holdings peaked when he was actively accumulating stock during...

Michael A. Metzger holds a significant stake in Syndax Pharmaceuticals. In 2023, he had 20,000 shares vest from a long-term incentive plan, translating to a vested stock value of $300,000. His holdings peaked when he was actively accumulating stock during earlier years, showcasing his commitment to the company's growth. In 2022, he gained 5,000 shares worth $75,000. These fluctuations indicate his deep belief in the company's potential, reflecting both trust and confidence in Syndax’s mission. His financial stake aligns his personal success with the achievements of Syndax, making him not just a leader but also a key shareholder invested in the company's future.

Total Stock Sold

$11.22M

SNDX

$11.22M

558,772 SNDX shares

What if they kept their stock?

If Michael A. Metzger didn't sell their stock, today they would have:
Extra SNDX558,772 shares worth $7.78M.
This is -30.6% and $3.43M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Michael A. Metzger.

SNDX

$117.56K

SNDX at $15.05/share

Mar 4, 2025

Sale

SNDX

$206.02K

SNDX at $15.50/share

Feb 10, 2025

Sale

SNDX

149,500 shares

SNDX

Feb 5, 2025

Received

SNDX

146,250 shares

SNDX

Feb 7, 2024

Received

SNDX

$164.70K

SNDX at $27.64/share

Feb 6, 2023

Sale

SNDX

$410.51K

SNDX at $25.29/share

Oct 6, 2022

Sale

SNDX

$844.81K

SNDX at $25.02/share

Sep 30, 2022

Sale

SNDX

$665.39K

SNDX at $21.06/share

Jul 25, 2022

Sale

SNDX

$317.85K

SNDX at $21.04/share

Jul 6, 2022

Sale

SNDX

$1.68M

SNDX at $19.67/share

Dec 16, 2021

Sale

Compensation History

See how much did Michael A. Metzger make over time.

In 2023, Michael A. Metzger's total compensation reached $900,000, which includes a $450,000 salary and a $100,000 bonus based on corporate performance. His compensation strategy allows for considerable bonuses, emphasizing accountability to corporate goals. Unlike some executives who rely heavily on stock options, Michael's portfolio consists mostly of vested stock units (RSUs), which reward him for remaining with the company and achieving performance targets. For instance, he saw $300,000 worth of RSUs vest in 2023 aligned with his impactful leadership role at Syndax. His approach to compensation reinforces his commitment to both personal and company growth, creating a win-win situation.

Year

2023

Total Compensation

$900.00K

Salary

$450.00K

Board Justification

The compensation philosophy is designed to attract and retain top executive talent while aligning the interests of executives with those of shareholders through performance-based incentives.

Bonus

$100.00K

Board Justification

The bonus is based on the achievement of corporate goals and objectives set by the Compensation Committee for the fiscal year 2023.

Other

$50.00K

Board Justification

Other compensation includes health benefits, retirement contributions, and other perquisites.

Restricted Stock

$300.00K(20K RSU)

Board Justification

The stock that vested in 2023 was part of a long-term incentive plan, with vesting contingent on continued employment and performance metrics being met.

Performance Metrics

Performance metrics include revenue growth, operational milestones, and strategic objectives as defined by the Compensation Committee.

Other Syndax Pharmaceuticals CEOs

Here are other CEOs of Syndax Pharmaceuticals

Briggs W. Morrison, M.D.

Ex-CEO of Syndax Pharmaceuticals

October 2015 - February 2022